Medicare AdvantagePrior AuthMedium impact
Vtama (tapinarof) (Revised)
Humana·Dermatology, Pediatrics·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 25, 2026
Summary
Humana has revised its prior authorization policy for Vtama (tapinarof) effective January 1, 2026, with an update dated May 27, 2026. This policy establishes specific prior authorization requirements for Vtama 1% cream coverage in Medicare Advantage plans for two indications: plaque psoriasis (requiring BSA ≥3% with prior treatment/contraindication/intolerance to topical corticosteroids AND vitamin D products, or face/sensitive area involvement) and atopic dermatitis (requiring moderate-to-severe diagnosis, ≥5% BSA, and prior treatment/intolerance to both topical corticosteroids and calcineurin inhibitors). Billing teams must implement prior authorization verification workflows and ensure prescribers document all required clinical criteria before claim submission.
Action Required
Before January 1, 2026: Billing team must update claim submission workflows to require prior authorization verification for all Vtama (tapinarof) prescriptions billed to Humana Medicare Advantage plans. Create/update intake forms and encounter documentation templates to capture: (1) diagnosis confirmation (plaque psoriasis vs. atopic dermatitis), (2) affected BSA percentage, (3) prior treatment history with specific topical corticosteroids and vitamin D products (for psoriasis) or calcineurin inhibitors (for dermatitis), and (4) clinical rationale (e.g., sensitivity of affected body area). Train front desk, clinical staff, and providers to submit complete prior authorization requests through Humana's PAL (Preauthorization and Notification List) system at www.humana.com/PAL before dispensing. Claims submitted without completed prior authorization will be denied. For atopic dermatitis in children under 2 years, note that calcineurin inhibitor history is not required but all other criteria must be met.